CSPC Pharmaceutical Group (SEHK:1093) is back in focus after reporting half year 2026 results, announcing a higher interim dividend and updating investors on several oncology drug milestones in China.
The recent half year 2026 earnings and oncology updates appear to have fed directly into CSPC Pharmaceutical Group’s share price momentum, with a 90 day share price return of 36.85% and a 30 day gain of 14.76% helping lift the stock to HK$9.525. The 3 year total shareholder return of 81.14% points to a much stronger long term track record than the modest 1 year total shareholder return of 1.73%, suggesting that short term momentum is improving from a relatively muted base.
Scan how CSPC Pharmaceutical Group compares with other healthcare and pharma stocks showing strong momentum and fundamentals by reviewing the hand picked list of solid balance sheet and fundamentals (424 results) in the same space.
Bulls now point to CSPC Pharmaceutical Group’s sharp earnings rebound and oncology pipeline progress. Bears highlight prior earnings volatility. The next step is to see which story current valuation supports more convincingly.
Preferred Price-to-Earnings of 12.6x: Is it justified?
CSPC Pharmaceutical Group is currently trading on a P/E of 12.6x, which sits below several valuation reference points and provides context to the recent share price strength.
The P/E ratio compares the current share price to earnings per share. For a healthcare group like CSPC Pharmaceutical Group, it is a simple way for investors to gauge how much the market is willing to pay for each unit of profit from its pharmaceutical and functional food businesses across Mainland China and international markets.
According to the SWS assessment, the stock is trading at an estimated 17.8% discount to fair value, with CSPC Pharmaceutical Group at HK$9.53 versus an internal future cash flow value of HK$11.59. On this metric, the market price implies a lower valuation than the SWS DCF based estimate of future cash flows.
The current P/E of 12.6x is also below the estimated fair P/E of 13.9x, and well below the peer average of 22x and the Hong Kong pharmaceuticals industry average of 13.4x. That is a clear gap that suggests investors are pricing CSPC Pharmaceutical Group at a lower earnings multiple than both its immediate peers and what the fair ratio analysis implies the market could potentially move toward.
Explore the SWS fair ratio for CSPC Pharmaceutical Group
Result: Preferred multiple of price-to-earnings of 12.6x (UNDERVALUED)
However, investors in CSPC Pharmaceutical Group still need to weigh the recent net income decline of 7.04% and prior earnings volatility as possible pressure points.
Find out about the key risks to this CSPC Pharmaceutical Group narrative.
Another view on CSPC Pharmaceutical Group’s value
While the current 12.6x P/E and fair ratio work in CSPC Pharmaceutical Group’s favour, the SWS DCF model also points to value. It puts fair value at HK$11.59 per share versus today’s HK$9.53, which implies the stock trades at a 17.8% discount. The question is whether you trust earnings multiples or future cash flows more.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSPC Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 274 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With CSPC Pharmaceutical Group showing a mix of pressures and positives, it makes sense to move quickly, review the detailed data, and form your own stance. To weigh up both sides in one place, start by reviewing the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond CSPC Pharmaceutical Group?
If CSPC Pharmaceutical Group has sharpened your focus on valuation and quality, now is a great time to cast the net wider and line up your next watchlist candidates.
- Target resilient opportunities by scanning a 295 resilient stocks with low risk scores that may help you focus on companies with steadier profiles.
- Hunt for quality at attractive prices by reviewing a 274 high quality undervalued stocks that already filters for strong fundamentals.
- Strengthen your income playbook by checking out a 411 dividend fortresses that highlights higher yielding stocks for further research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com